SCHEMBL5653203

SCHEMBL5653203

Cc1cccc2[nH]c(-c3ccc(C(=O)NC4CC(C)(C)NC(C)(C)C4)cc3)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 2/20 0.54
EZH2 Q15910 5/20 0.53
KDM4E B2RXH2 2/20 0.53
NPC1 O15118 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 2/20 0.53
HPGD P15428 2/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HSD17B10 Q99714 2/20 0.53
GLA P06280 1/20 0.52
MGAM O43451 3/20 0.51
GAA P10253 3/20 0.51
SI P14410 3/20 0.51
MGAM2 Q2M2H8 3/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652125 0.90 EZH2 (0.53) EZH2GLAMEN1KMT2AL3MBTL1
SCHEMBL5649687 0.87 GLA (0.57) EZH2HSD17B10GLAMGAMGAA
SCHEMBL5653984 0.85 GLA (0.52) HPSEEZH2KDM4EALDH1A1TP53
SCHEMBL5652390 0.85 L3MBTL1 (0.53) EZH2HSD17B10GLAMGAMGAA
SCHEMBL5653210 0.84 EZH2 (0.53) EZH2HSD17B10GLAMEN1KMT2A
SCHEMBL5648647 0.83 MEN1 (0.52) EZH2HSD17B10GLAMGAMGAA
SCHEMBL5649972 0.81 GLA (0.49) EZH2KDM4EALDH1A1TP53HSD17B10
SCHEMBL5652627 0.81 HPSE (0.51) HPSEEZH2GLAMEN1KMT2A
SCHEMBL5651443 0.80 EZH2 (0.57) EZH2GLAMEN1KMT2AL3MBTL1
SCHEMBL5648453 0.80 GLA (0.55) EZH2HSD17B10GLAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HPSE 3728/4885EZH2 879/4885KDM4E 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.